Background: α-Glucosidase inhibitors (AGIs) have been reported for their clinical potential
against postprandial hyperglycemia, which is responsible for the risks associated with diabetes mellitus
2 and cardiovascular diseases (CVDs). Besides, a number of compounds have been reported as potent
AGIs, several side effects are associated with them.
Methods: The aim of present work is to explore new and potent molecules as AGIs. Therefore, a library
of dibenzoazepine linked triazoles (1-15) was studied for their in vitro α-glucosidase inhibitory
activity. The binding modes of potent compounds in the active site of α-glucosidase enzyme were also
explored through molecular docking studies.
Results and Conclusion: Among the reported triazoles, compounds 3-9, 11, and 13 (IC50 = 6.0 ± 0.03
to 19.8 ± 0.28 µM) were found to be several fold more active than the standard drug acarbose (IC50 =
840 ± 1.73 µM). Compound 5 (IC50 = 6.0 ± 0.03 µM) was the most potent AGIs in the series, about 77-
fold more active than acarbose. Therefore, dibenzoazepine linked-triazoles described here can serve as
leads for further studies as new non-sugar AGIs.
背景:α-
葡萄糖苷酶
抑制剂(AGIs)在对抗餐后高血糖方面显示出临床潜力,而餐后高血糖与2型糖尿病和心血管疾病(CVDs)的风险相关。此外,已经报告有多种化合物作为有效的AGIs,但它们也伴随一些副作用。
方法:本研究的目的是探索新的有效分子作为AGIs。因此,研究了一个含有二苯并氮杂环的三唑化合物库(1-15)对α-
葡萄糖苷酶的体外抑制活性。还通过分子对接研究探索了这些有效化合物在α-
葡萄糖苷酶酶活性位点的结合方式。
结果与结论:在报告的三唑化合物中,化合物3-9、11和13(IC50 = 6.0 ± 0.03至19.8 ± 0.28 µM)比标准药物
阿卡波糖(IC50 = 840 ± 1.73 µM)活性高出数倍。化合物5(IC50 = 6.0 ± 0.03 µM)是系列中最有效的AGIs,大约比
阿卡波糖活性高出77倍。因此,这里描述的二苯并氮杂环连接的三唑化合物可以作为新型非糖AGIs进一步研究的先导。